The pharmacology of neurokinin receptors in addiction: prospects for therapy.

IF 5.1 Q1 SUBSTANCE ABUSE
Substance Abuse and Rehabilitation Pub Date : 2015-09-07 eCollection Date: 2015-01-01 DOI:10.2147/SAR.S70350
Alexander J Sandweiss, Todd W Vanderah
{"title":"The pharmacology of neurokinin receptors in addiction: prospects for therapy.","authors":"Alexander J Sandweiss,&nbsp;Todd W Vanderah","doi":"10.2147/SAR.S70350","DOIUrl":null,"url":null,"abstract":"<p><p>Addiction is a chronic disorder in which consumption of a substance or a habitual behavior becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) is an undecapeptide and was the first neuropeptide of the neurokinin family to be discovered. The subsequent decades of research after its discovery implicated SP and its neurokinin relatives as neurotransmitters involved in the modulation of the reward pathway. Here, we review the neurokinin literature, giving a brief historical perspective of neurokinin pharmacology, localization in various brain regions involved in addictive behaviors, and the functional aspects of neurokinin pharmacology in relation to reward in preclinical models of addiction that have shaped the rational drug design of neurokinin antagonists that could translate into human research. Finally, we will cover the clinical investigations using neurokinin antagonists and discuss their potential as a therapy for drug abuse. </p>","PeriodicalId":22060,"journal":{"name":"Substance Abuse and Rehabilitation","volume":"6 ","pages":"93-102"},"PeriodicalIF":5.1000,"publicationDate":"2015-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/SAR.S70350","citationCount":"30","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance Abuse and Rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/SAR.S70350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 30

Abstract

Addiction is a chronic disorder in which consumption of a substance or a habitual behavior becomes compulsive and often recurrent, despite adverse consequences. Substance p (SP) is an undecapeptide and was the first neuropeptide of the neurokinin family to be discovered. The subsequent decades of research after its discovery implicated SP and its neurokinin relatives as neurotransmitters involved in the modulation of the reward pathway. Here, we review the neurokinin literature, giving a brief historical perspective of neurokinin pharmacology, localization in various brain regions involved in addictive behaviors, and the functional aspects of neurokinin pharmacology in relation to reward in preclinical models of addiction that have shaped the rational drug design of neurokinin antagonists that could translate into human research. Finally, we will cover the clinical investigations using neurokinin antagonists and discuss their potential as a therapy for drug abuse.

Abstract Image

成瘾中神经激肽受体的药理学:治疗前景。
成瘾是一种慢性疾病,对某种物质的消费或习惯性行为变得强迫性,并且经常反复发作,尽管有不良后果。p物质(SP)是一种非肽,是神经激肽家族中第一个被发现的神经肽。在其发现之后的几十年的研究表明SP及其神经激肽亲戚是参与调节奖赏通路的神经递质。在这里,我们回顾了神经激肽的文献,给出了神经激肽药理学的简要历史观点,在涉及成瘾行为的不同大脑区域的定位,以及神经激肽药理学在成瘾的临床前模型中与奖励相关的功能方面,这些方面已经形成了神经激肽拮抗剂的合理药物设计,可以转化为人类研究。最后,我们将介绍使用神经激肽拮抗剂的临床研究,并讨论它们作为药物滥用治疗的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
9
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信